Glycogen storage disease type Ia (GSD Ia; OMIM #232200) is an ultra-rare inherited metabolic disorder caused by deficient glucose-6-phosphatase (G6Pase; EC 3.1.3.9) activity, which hydrolyzes glucose-6-phosphate (G6P), to produce glucose in the endoplasmic reticulum lumen in the final common pathway of glycogenolysis and gluconeogenesis. Classically, symptoms and signs in the first year of life include severe fasting intolerance, failure to thrive, and hepatomegaly, biochemically characterized by nonketotic hypoglycemia, fasting hyperlactatemia, hyperuricaemia, and hyperlipidaemia (Fig. 1), but few milder phenotypes are described.

Dietary management is the cornerstone of treatment aiming at maintenance of euglycemia, prevention of secondary metabolic perturbations, and long-term complications including the liver (hepatocellular adenomas and carcinomas).

Case Report

A 25-year-old woman presented with acute abdominal pain in the right upper quadrant and fever at the emergency department of a local hospital in January 2017. Laboratory tests displayed hypoglycemia (glucose 2.5 mmol/L), hyperlactatemia (lactate 9.1 mmol/L), and hyperlipidemia (triglycerides 10.6 mmol/L, cholesterol 6.1 mmol/L), without urinary ketones. She was treated with an intravenous bolus of 100 mL of glucose 10%, subsequent 125-mL/h maintenance infusion of sodium chloride 0.45% and glucose 5.0%, and antibiotics under the working diagnosis of a sepsis with an abdominal focus. Symptoms recovered quickly, but glucose concentrations remained relatively low.

At that time, medical history revealed that she had been referred by the general practitioner in September 2016 because of fatigue, weight loss, nocturnal sweating, hypermenorrhea, and nose bleedings, associated with microcytic anemia (hemoglobin 4.5 mmol/L; mean corpuscular volume 59 fl). Abdominal imaging (December 2016) displayed hepatomegaly with multiple hepatocellular adenomas (Fig. 2A), based on which, the radiologist reported a suspicion of glycogen storage disease. After referral to the center of expertise, the working diagnosis of GSD Ia was established.

Our patient is the child of first-degree cousins of Moroccan ancestry and had hospital admissions in childhood due to various infections. Since 1993, our patient had suffered tiredness, for which she was followed by the local pediatrician. Between 2000 and 2006, she was evaluated by the pediatric immunologist and gastroenterologist because of failure to thrive, hepatomegaly, and persisting increase of erythrocyte sedimentation rate. She was growing at –2.5 SDs, below her target range, with delayed bone age, and...
increased plasma uric acid concentrations were not recognized. She reported obvious signs of fasting intolerance; during the day, she frequently drank juices, and during the nights, she was hungry, sweating, and woke at least 1-2 times to eat or drink carbohydrate-containing substances. She got married in March 2016 and was working a full-time job as an elementary school teacher.

Dietary management was started with restrictions of sucrose, fructose, and lactose and frequent, small doses of uncooked cornstarch, finally reaching 40 g every 4 hours, day and night. She was advised to discontinue her estrogen-containing oral contraceptive (that she had been using since March 2016) and to use alternative contraception. After 5 weeks, nocturnal cornstarch management was changed toward 120 g of extended-release cornstarch for 8 hours of sleep.

Regarding the liver adenomas, we aimed at a conservative, nonsurgical management and repeating liver imaging to evaluate the effect of the discontinuation of uncooked cornstarch, finally reaching 40 g every 4 hours, day and night. She was advised to discontinue her estrogen-containing oral contraceptive (that she had been using since March 2016) and to use alternative contraception. After 5 weeks, nocturnal cornstarch management was changed toward 120 g of extended-release cornstarch for 8 hours of sleep.

Regarding the liver adenomas, we aimed at a conservative, nonsurgical management and repeating liver imaging to evaluate the effect of the discontinuation
As reported, a significant decrease in adenoma sizes was observed in February 2018 (see legend Fig. 2). Meanwhile, Sanger sequencing of the \( G6PC \) gene revealed homozygosity for the c.1039C>T (p.Gln347X) mutation, confirming our working hypothesis.

**Discussion**

After the classical textbook phenotype of monogenic disorders, like GSD Ia, the complete clinical and biochemical spectrum is discovered. GSD Ia is an ultra-rare, but treatable, inherited metabolic disorder that can be diagnosed based on detailed history taking, physical examination, and standard laboratory investigations, even in relatively mildly presenting adult patients. Basic, but targeted, clinical testing is warranted to exclude GSD Ia in patients presenting atypical liver adenomas. Rapid diagnosis and proper dietary treatment are important to prevent symptomatic hypoglycemias, acute life-threatening metabolic perturbations, and chronic complications, related to liver adenomas and kidney disease.

**Acknowledgment:** The authors thank Anna Sieben (Institute for Medical Education, Faculty of Medical Sciences, University of Groningen), who created the interactive 3D-model for educational purposes.

**REFERENCES**

1) Bali DS, Chen YT, Austin S, Goldstein JL. Glycogen Storage Disease Type I. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al, eds. Seattle, WA: GeneReviews(R); 1993.

2) Cassiman D, Libbrecht L, Verslype C, Meersseman W, Troisi R, Zucman-Rossi J, et al. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type Ia. J Hepatol 2010;53:213-217.

3) Beegle RD, Brown LM, Weinstein DA. Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. JIMD Rep 2015;18:23-32.

Author names in bold designate shared co-first authorship.